Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
$0.79
+2.5%
$0.97
$0.57
$3.85
$25.11M0.2790,598 shs25,690 shs
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$2.28
-2.1%
$1.85
$1.09
$7.50
$28.66M0.77382,868 shs38,518 shs
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$2.11
$2.28
$1.83
$9.19
$28.44M1.14138,465 shs75,535 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$4.47
-1.8%
$3.96
$1.75
$6.92
$7.48M1.39176,613 shs31,549 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
+2.47%-3.63%-19.70%-33.70%-77.46%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-2.15%-2.56%+24.59%+23.91%-69.80%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
0.00%-1.86%0.00%-30.36%-35.28%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-1.76%-5.50%+46.08%+44.66%+36.70%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
$0.79
+2.5%
$0.97
$0.57
$3.85
$25.11M0.2790,598 shs25,690 shs
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$2.28
-2.1%
$1.85
$1.09
$7.50
$28.66M0.77382,868 shs38,518 shs
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$2.11
$2.28
$1.83
$9.19
$28.44M1.14138,465 shs75,535 shs
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$4.47
-1.8%
$3.96
$1.75
$6.92
$7.48M1.39176,613 shs31,549 shs
Ten Starter Stocks For Beginners to Buy Now Cover

Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
+2.47%-3.63%-19.70%-33.70%-77.46%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-2.15%-2.56%+24.59%+23.91%-69.80%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
0.00%-1.86%0.00%-30.36%-35.28%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-1.76%-5.50%+46.08%+44.66%+36.70%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
3.00
Buy$3.30318.25% Upside
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
3.00
Buy$4.0075.44% Upside
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
3.00
Buy$10.00373.93% Upside
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest SNOA, CASI, DARE, and AKTX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
9/9/2025
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$1.60
9/4/2025
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeHoldBuy$8.00
9/3/2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingBuy$4.00
7/18/2025
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
Maxim Group
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Initiated CoverageBuy$5.00
(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/A$0.84 per shareN/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
$28.54M0.98N/AN/A$0.12 per share19.00
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
$10K2,844.28N/AN/A($0.69) per share-3.06
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
$14.29M0.51N/AN/A$2.73 per share1.64
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
-$19.79MN/A0.00N/AN/A-78.03%-31.62%9/25/2025 (Estimated)
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$39.26M-$2.89N/AN/A-148.55%-972.55%-99.07%11/12/2025 (Estimated)
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$4.05M-$2.14N/AN/AN/AN/AN/A-103.70%11/13/2025 (Estimated)
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$3.46M-$2.46N/AN/AN/A-23.87%-50.00%-16.79%11/6/2025 (Estimated)

Latest SNOA, CASI, DARE, and AKTX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
9/25/2025Q2 2025
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
-$0.09N/AN/AN/AN/AN/A
8/29/2025Q2 2025
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
-$0.47-$0.86-$0.39-$0.86$6.28 million$4.18 million
8/14/2025Q2 2025
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
-$0.55-$0.45+$0.10-$0.45$0.14 million($0.02) million
8/7/2025Q1 2026
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.51-$0.37+$0.14-$0.76$4.26 million$4.01 million
6/17/2025Q4 2025
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
-$0.73-$0.15+$0.58-$0.48$4.44 million$3.75 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/AN/AN/AN/AN/A
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/AN/AN/AN/AN/A
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/AN/AN/AN/AN/A
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
N/A
0.19
0.19
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
N/A
0.48
0.39
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
N/A
0.34
0.34
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
N/A
2.70
1.92

Institutional Ownership

CompanyInstitutional Ownership
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
5.06%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
22.23%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
6.70%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1.95%

Insider Ownership

CompanyInsider Ownership
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
38.10%
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
21.24%
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
4.80%
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
24.59%
CompanyEmployeesShares OutstandingFree FloatOptionable
Akari Therapeutics PLC stock logo
AKTX
Akari Therapeutics
932.62 million20.19 millionNot Optionable
CASI Pharmaceuticals Inc. stock logo
CASI
CASI Pharmaceuticals
18012.30 million9.69 millionOptionable
Dare Bioscience, Inc. stock logo
DARE
Dare Bioscience
3013.48 million12.83 millionNot Optionable
Sonoma Pharmaceuticals, Inc. stock logo
SNOA
Sonoma Pharmaceuticals
1801.64 million1.24 millionNot Optionable

Recent News About These Companies

Sonoma Pharmaceuticals expands into UK market

New MarketBeat Followers Over Time

Media Sentiment Over Time

Akari Therapeutics stock logo

Akari Therapeutics NASDAQ:AKTX

$0.79 +0.02 (+2.47%)
Closing price 09/12/2025 03:59 PM Eastern
Extended Trading
$0.79 +0.01 (+0.63%)
As of 09/12/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on developing advanced therapies for autoimmune and inflammatory diseases. Its lead product candidate is nomacopan, a second-generation complement inhibitor that prevents inflammatory and prothrombotic activities, including paroxysmal nocturnal hemoglobinuria, Guillain-Barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid, as well as pre-clinical program developing long-acting PASylated-nomacopan for treatment of geographic atrophy secondary to dry age-related macular degeneration. The company is based in London, the United Kingdom.

CASI Pharmaceuticals stock logo

CASI Pharmaceuticals NASDAQ:CASI

$2.28 -0.05 (-2.15%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$2.28 0.00 (0.00%)
As of 09/12/2025 04:04 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

CASI Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics and pharmaceutical products in the People's Republic of China, the United States, and internationally. It offers EVOMELA, an intravenous formulation of melphalan for use as a conditioning treatment prior to stem cell transplantation, and as a palliative treatment for patients with multiple myeloma. The company's other hematology/oncology assets in pipeline include CNCT 19, an autologous CD19 CAR-T investigative product; BI-1206, novel anti-Fc?RIIB antibody, for the treatment of solid tumors and relapsed/refractory non-hodgkin lymphoma; CB-5339, a novel VCP/p97 inhibitor that focuses on valosin-containing protein (VCP)/p97 as a novel target in protein homeostasis, DNA damage response, and other cellular stress pathways for therapeutic use in the treatment of patients with various malignancies; CID-103, a human IgG1 anti-CD38 monoclonal antibody; and Thiotepa, a chemotherapeutic agent, which has various indications, including use as a conditioning treatment for use prior to certain allogeneic haemopoietic stem cell transplants. The company has licensing agreements with Juventas Cell Therapy Ltd.; BioInvent International AB; Black Belt Therapeutics Limited; Cleave Therapeutics, Inc.; and Acrotech Biopharma L.L.C. to develop and commercialize its commercial product EVOMELA. It also has distribution agreements with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd; Pharmathen Global BV; and Riemser Pharma GmbH. CASI Pharmaceuticals, Inc. was incorporated in 1991 and is based in Beijing, the People's Republic of China.

Dare Bioscience stock logo

Dare Bioscience NASDAQ:DARE

$2.11 0.00 (0.00%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$2.11 0.00 (-0.19%)
As of 09/12/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Daré Bioscience, Inc., a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older. It is developing Ovaprene, a hormone-free, monthly intravaginal contraceptive; Sildenafil Cream, a cream formulation of sildenafil for topical administration to the female genitalia on demand for the treatment of female sexual arousal disorder; DARE-HRT1 to treat moderate to-severe vasomotor symptoms in menopausal hormone therapy; DARE-VVA1 for the treatment of moderate-to-severe dyspareunia or pain during sexual intercourse; and DARE-CIN to treat cervical intraepithelial neoplasia and other human papillomavirus related pathologies. The company is also developing DARE-PDM1 for the treatment of primary dysmenorrhea; DARE-204 and DARE-214, an injectable formulations contraception of etonogestrel designed to provide contraception over 6-month and 12-month periods; DARE-FRT1, an intravaginal ring designed to deliver bio-identical progesterone for luteal phase support as part of an in vitro fertilization treatment plan; and DARE-PTB1 for the prevention of preterm birth. In addition, it is developing DARE-LARC1, a contraceptive implant delivering levonorgestrel with a woman-centered design that controlled contraceptive option; DARE-LBT, a novel hydrogel formulation for vaginal delivery of live biotherapeutics to support vaginal health; DARE-GML, a multi-target antimicrobial agent; DARE-RH1, a novel approach to non-hormonal contraception for men and women by targeting the CatSper ion channel; and DARE-PTB2 for the prevention and treatment of idiopathic preterm birth through inhibition of a stress response protein. Daré Bioscience, Inc. is headquartered in San Diego, California.

Sonoma Pharmaceuticals stock logo

Sonoma Pharmaceuticals NASDAQ:SNOA

$4.47 -0.08 (-1.76%)
Closing price 09/12/2025 04:00 PM Eastern
Extended Trading
$4.47 0.00 (0.00%)
As of 09/12/2025 07:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Sonoma Pharmaceuticals, Inc., develops and produces stabilized hypochlorous acid (HOCl) products for wound care, animal health care, eye care, oral care, and dermatological conditions in the United States, Latin America, Europe, Asia, and internationally. The company offers Regenacyn, a prescription scar gel; Pediacyn, a pediatric dermatology and wound care product for over-the-counter (OTC) use; Epicyn, an Antimicrobial Facial Cleanser; Levicyn, an HOCl based prescription and OTC product to use and relieve skin irritations, lacerations, abrasions, and burns; Celacyn, a scar management gel; and SebuDerm to manage and relieve the burning, itching, erythema, scaling, and pain associated with seborrhea and seborrheic dermatitis. It also provides Gramaderm for the treatment of topical mild to moderate acne; Microcyn, a HOCl-based topical line of products designed to stimulate expedited healing by targeting a wide range of pathogens; Ocucyn eyelid and eyelash cleanser; Microdacyn60 oral care solution for the treatment of mouth and throat infections; and Podiacyn, a foot care product. In addition, the company offers MicrocynAH, an HOCl-based solution designed to relieve common symptoms of hot spots, scratches, skin rashes post-surgical sites, and irritated animal skin for healing; MicrocynVS, a veterinarian-strength animal care product used in vet clinics and animal hospitals; Nanocyn, a hospital-grade disinfectant; Acuicyn, an antimicrobial prescription solution for the treatment of blepharitis and the daily hygiene of eyelids and lashes; MucoClyns for the use in emergencies and safe to use on mucous membranes, cuts, abrasions, burns, and body surfaces; Endocyn root canal irrigation solutions; and Sinudox for nasal irrigation. The company was formerly known as Oculus Innovative Sciences, Inc. and changed its name to Sonoma Pharmaceuticals, Inc. in December 2016. Sonoma Pharmaceuticals, Inc. was incorporated in 1999 and is based in Boulder, Colorado.